SANTA CLARA, Calif.--(BUSINESS WIRE)--XenoPort, Inc. (NASDAQ:XNPT) announced today that it has been awarded a grant from The Michael J. Fox Foundation for Parkinson’s Research to support a preclinical study of the efficacy and safety of a novel, orally administered prodrug of acamprosate in reducing L-Dopa induced dyskinesias (LID) in a pre-clinical model of Parkinson’s disease. The grant of $194,000 was awarded under the Foundation's Therapeutics Development Initiative Fall 2010 Program aimed at supporting preclinical development of Parkinson's disease therapies that have the potential for fundamentally altering disease course and improving treatment of symptoms above and beyond current standards of care.
